[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Société Française d'Endoscopie Digestive\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":154},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,72,98,123],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100619380","multicenter-prospective-cohort-on-esophageal-endoscopic-submucosal-dissection-100619380",false,"NCT07343869","Multicenter Prospective Cohort on Esophageal Endoscopic Submucosal Dissection","Prospective Multicenter Cohort on Esophageal Submucosal Dissection: Evaluation of Technical, Oncological, and Organizational Outcomes in Real-Life Practice","FEO","Inclusion Criteria:\n\n* Adults (≥ 18 years old)\n* Patients referred for endoscopic resection of an esophageal lesion and treated by submucosal dissection\n* Patients managed in one of the participating centers\n* Patient who has received oral and written information about the study and has not objected to participation\n* Patients covered by a social security or health insurance scheme.\n\nExclusion Criteria:\n\n* Patient refusal after reading the information sheet\n* Patient under legal protection (guardianship, curatorship, court-ordered protection)\n* Inability to inform the patient due to cognitive impairment, language barrier, or medical emergency\n* Patients previously included for another lesion in the same study\n* Pregnant or breastfeeding women.\n* Patient deprived of liberty.\n* Patient currently enrolled in another clinical trial.","ALL","18 Years",{"count":20,"type":21},750,"ESTIMATED","5 Years","OBSERVATIONAL","In France in 2018, there were an estimated 2,074 new cases of esophageal adenocarcinoma and 3,224 cases of squamous cell carcinoma. The estimated deaths from esophageal cancer were 3,725, with a standardized 5-year net survival rate of 20% for cases diagnosed between 2010 and 2015, mainly due to late diagnosis.\n\nSurgery was historically the standard treatment for localized disease but carries significant morbidity. Over the past decade, endoscopic treatments, particularly endoscopic submucosal dissection (ESD), have become the reference approach for superficial esophageal cancers.\n\nAfter endoscopic resection, histological analysis allows classification of recurrence risk into very low, low, and high categories. Predicting lymph node or distant recurrence is complex, depending on factors such as depth of wall infiltration, lymphovascular invasion, and tumor differentiation. The frequent combination of unfavorable histological features may have led to an overestimation of lymph node involvement risk in T1b cancers.\n\nESD is widely performed in France, with over 1,600 procedures reported in 2023 for esophageal and gastric lesions, demonstrating the feasibility of a large observational study.\n\nThis multicenter French cohort will evaluate technical, oncological, and organizational outcomes of esophageal ESD, including overall survival, recurrence-free survival, and management of residual Barrett's esophagus. It will also identify predictive factors for treatment success, recurrence, and complications, providing real-world evidence to guide patient management.",[26,27,28,29],"Superficial Esophageal Cancer","Oesophageal Adenocarcinoma","Oesophageal Squamous Cell Carcinoma","Barretts Esophagus With Dysplasia",[31,32,33,34],"Endoscopic esophageal disection","Endoscopic resection","Endoscopic submucosal dissection","Curative resection","NOT_YET_RECRUITING","2026-01-07",{"date":38,"type":39},"2026-01-15","ACTUAL",{"date":41,"type":21},"2026-02-01",{"date":43,"type":21},"2036-02-01",{"name":45,"class":46},"Société Française d'Endoscopie Digestive","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":4},"100566604","national-registry-of-obesity-treatment-by-endosleeve-100566604","NCT06657339","National Registry of Obesity Treatment by Endosleeve","Inclusion Criteria:\n\n* Age over 18 years;\n* Patient with a body mass index (BMI) ≥ 30 kg\u002Fm²;\n* Signed informed consent\n\nExclusion Criteria:\n\n* Contraindication to performing an upper endoscopy or using an endoscopic plication system according to the instructions for use (IFU);\n* Presence of an ulcer in the gastric body or fundus;\n* Achalasia, severe esophagitis (Los Angeles grade C or D);\n* ENT or esophageal malformation;\n* Gastrointestinal disease (including stenosis), history of previous gastric surgery (including bariatric surgery, previous endoscopic gastroplasty);\n* Congestive gastropathy, gastric polyposis, gastric or esophageal varices, risk of gastric tumor disease due to personal or family history;\n* Positive Helicobacter pylori status with failed eradication treatments;\n* Uncontrolled or severe eating disorder or psychiatric illness;\n* Substance abuse or chronic alcoholism;\n* Severe renal insufficiency (stage 4 or 5), Cirrhosis Child B or C;\n* Anticoagulant or antiplatelet treatment that cannot be stopped or replaced according to international recommendations (ESGE 2021);\n* Coagulation or hemostasis disorders (PT \\\u003C 60%, platelets \\\u003C 60,000\u002Fmm³);\n* Mental deficiency of the subject making participation in the trial impossible;\n* Patient not affiliated with a social security scheme;\n* Pregnant women, breastfeeding individuals;\n* Inability to understand or sign the informed consent.","90 Years",{"count":56,"type":21},354,"Obesity and overweight have emerged as public health problems of a pandemic nature, significantly reducing the life expectancy of those affected. Obesity has a considerable medico-economic impact, linked to the treatments it requires and its comorbidities. Currently, the prevention of obesity in our Western societies is not effective enough, as the prevalence and incidence of obesity and overweight continue to rise worldwide. In France, the therapeutic management of this condition is governed by the HAS and is summarized as a surgical approach for type 2 obesity with comorbidity or type 3 obesity, with three authorized methods that have shown sufficient evidence: gastric banding, sleeve gastrectomy (or longitudinal sleeve gastrectomy), and Roux-en-Y gastric bypass.\n\nWith the advent of organ-preserving interventional endoscopy, the systematic use of these surgical methods, although effective for total weight loss and excess weight loss, raises questions. Indeed, these new therapeutic endoscopic approaches, which are less invasive, less costly, and respectful of anatomy, currently show convincing cohort results in the short term (12 to 24 months) and require confirmation of their effectiveness and safety in the long term (5 years) so that they can become first-line therapeutic methods in the near future. At the request of the HAS in its self-referral of 2020 and then in 2022, this prospective registry aims to confirm the effectiveness and safety of the endosleeve (or endoscopic sleeve) in the long-term therapeutic management of obesity within the framework of everyday practice in national reference centers for obesity treatment.",[59],"Obesity",[61,62,63],"Endosleeve","Endoscopic gastroplasty","Endoscopic suture","2024-10-21",{"date":66,"type":39},"2024-10-24",{"date":68,"type":21},"2024-12",{"date":70,"type":21},"2029-12",{"name":45,"class":46},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":4},"100561788","endoscopic-treatment-of-zenkers-diverticulum-zenktun-100561788","NCT06594718","Endoscopic Treatment of Zenker's Diverticulum (ZENKTUN)","Endoscopic Treatment of Zenker's Diverticulum: a Prospective Observational Study Comparing Tunnelization (Z-POEM) Versus Non-Tunnelization Techniques","Inclusion Criteria:\n\n* Patients with symptomatic Zenker's diverticulum (Augsburg score ≥5 )\n* Diagnostic evaluation including esophagogastroduodenoscopy (EGD) and a barium swallow (TOGD) with measurement of the diverticulum's height.\n* Patient aged 18 years or older\n* Patient with ASA 1, ASA 2, ASA 3 status\n* No participation in another concurrent clinical study\n\nExclusion Criteria:\n\n* Patient under 18 years old\n* Patient with ASA 4 or ASA 5 status\n* Pregnant woman\n* Patient with coagulation disorders preventing the performance a polypectomy: PT \\\u003C 50%, Platelets \\\u003C 50,000\u002Fmm³, ongoing effective anticoagulation, or current clopidogrel use.\n* Patient who has already undergone initial endoscopic or surgical treatment for Zenker's diverticulum",{"count":80,"type":21},128,"Prospective comparative observational study in numerous reference centers in France, comparing Tunnelization (Z-POEM) versus Non-Tunnelization Techniques according to the usual practices. This is a prospective, comparative, observational, multicenter study with the primary objective of comparing the symptomatic recurrence rate one year after endoscopic tunnelization therapy (Z-POEM) versus non-tunnelization techniques in patients with symptomatic Zenker's diverticulum.",[83],"Zenker Diverticulum",[85,86,87,88,89],"Zenker's diverticulum","Z-POEM","Diverticuloscope","Knife Septotomy","Clutch Cutter","2024-09-10",{"date":92,"type":39},"2024-09-19",{"date":94,"type":21},"2024-10-31",{"date":96,"type":21},"2028-10-31",{"name":45,"class":46},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":108,"conditions":109,"keywords":111,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":47},"100557236","antibiotic-prophylaxis-for-eus-fna-of-pancreatic-cystic-lesions-100557236","NCT06535490","Antibiotic Prophylaxis for EUS-FNA of Pancreatic Cystic Lesions","Prevention of Infection After EUS-FNA of Pancreatic Cystic Lesions: A French Multicenter Prospective Comparative Observational Study","PrePaCyst","Inclusion Criteria:\n\n* Patient referred for diagnostic aspiration of a pancreatic cystic lesion\n* Patient aged 18 years or older\n* Patient with ASA 1, ASA 2, ASA 3 status\n* No participation in another concurrent clinical study\n\nExclusion Criteria:\n\n* Patient under 18 years old\n* Patient with ASA 4 or ASA 5 status\n* Pregnant woman\n* Patient with coagulation disorders preventing the performance of an EUS-FNA: PT \\\u003C 50%, platelets \\\u003C 50,000\u002Fmm³, current effective anticoagulation, ongoing clopidogrel, prasugrel, or ticagrelor treatment\n* Patient unable to personally express non-opposition or legally protected adult",{"count":107,"type":21},1702,"Large prospective comparative observational study in numerous reference centers in France, comparing infectious complications in patients admitted for pancreatic cystic lesions (PCL) aspiration performed with or without antibiotic prophylaxis (ATBp) according to the usual practices.\n\nThis is a prospective, comparative, observational, multicenter study, with the primary objective of comparing the infection rates in pancreatic cystic lesions (PCL) aspirated under EUS, with and without the administration of ATBp.\n\nA sample size of 1702 patients will be needed over a 3-year study period.",[110],"Pancreatic Cystic Lesion",[112,113,114],"EUS-FNA","Pancreatic cystic lesion","Antibiotic prophylaxis","2024-08-01",{"date":117,"type":39},"2024-08-02",{"date":119,"type":21},"2024-09-15",{"date":121,"type":21},"2027-10-15",{"name":45,"class":46},{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":134,"phases":135,"briefSummary":137,"conditions":138,"keywords":141,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":47},"100472427","anti-migration-system-for-anti-reflux-oeso-gastric-stent-antimig-100472427","NCT05431738","Anti-Migration System for Anti-reflux Oeso-gastric Stent (ANTIMIG)","Esophageal Stent With or Without Anti-migration Device for Tumors of the Gastroesophageal Junction: Multicenter Randomized Controlled Study. ANTIMIG Study","ANTIMIG","Inclusion Criteria:\n\n1. Patient of both sexes aged 18 or over.\n2. Patient admitted to one of the investigation centers for dysphagia due to tumoral stenosis of the gastroesophageal junction, locally advanced or metastatic.\n3. Patient ASA 1, ASA 2, ASA 3\n4. Absence of participation in another clinical study\n5. Signed Informed Consent\n6. Patients benefiting from the social security system.\n\nExclusion Criteria:\n\n1. Patient referred for stenosis by extrinsic compression by an extra digestive mass\n2. Patients with contraindications relating to the procedures essential for the introduction of a stent\n3. Mediastinal radiotherapy or esophageal surgery history\n4. Patient under 18 or over 90\n5. Patient ASA 4, ASA 5\n6. Pregnant Woman\n7. Patient unable to give personal consent\n8. Absence of signed informed consent","91 Years",{"count":133,"type":21},180,"INTERVENTIONAL",[136],"NA","The aim of this prospective, controlled, randomized, multicentre, single-blind study is to compare the rate of intragastric migration of 2 types of esophageal stents with and without an anti-migration device placed for locally advanced or metastatic malignant stenosis of the gastroesophageal junction.",[139,140],"Stent Migration","GastroEsophageal Cancer",[139,140,142,143,144],"Esophageal Stenosis","Esophageal cancer","Endoscopy","RECRUITING","2024-07-27",{"date":148,"type":39},"2024-07-30",{"date":150,"type":39},"2022-09-01",{"date":152,"type":21},"2025-09-01",{"name":45,"class":46},""]